| January 2 |
PRWT Acquires Chemical Manufacturing Facility from Merck & Co.,
Inc. |
| January 2 |
Biovail Announces Supply Agreement for Commercialization of
Extended-Release Tramadol |
| January 2 |
Use of Opioids to Treat Pain in Emergency Departments on the Rise,
but Racial Differences in Opioid Use Still Exist |
| January 2 |
IDM Pharma Announces Termination of Uvidem Development
Collaboration and Expected Restructuring in Connection With
Evaluation of Strategic Alternatives |
| January 2 |
Pfizer Inc Announces Completion of the Tender Offer Relating to
Outstanding Shares of Coley Pharmaceutical Group, Inc. |
| January 2 |
Beijing Med-Pharm Receives Business License for Alliance BMP
Limited |
| January 2 |
Covalence Ethical Ranking 2007 |
| January 3 |
Celgene/Pharmion Hart-Scott-Rodino (HSR) Thirty Day Waiting Period
Expires |
| January 3 |
Addex and Merck & Co., Inc. Enter License Agreement to Develop
a Drug Candidate for Schizophrenia |
| January 3 |
B-cell Chronic Lymphocytic Leukemia (B-CLL): Expanded Labeling for
MabCampath in Europe |
| January 3 |
Crucell Enters Agreement with Sanofi Pasteur for Next-generation
Biologicals Against Rabies |
| January 3 |
Phase Bioscience Announces New Collaboration with Centocor Research
and Development |
| January 3 |
Galapagos Enters Into Oncology Target Discovery Collaboration with
Janssen Pharmaceutica |
| January 3 |
Bruker AXS Announces Agreement to Acquire Elemental Analysis
Company JUWE Laborgeraete GmbH |
| January 3 |
Novacea Provides Corporate and Development Update |
| January 3 |
Pfizer to Appeal Canadian Federal Court Ruling on Lipitor Patent;
Court's Decision Will Have No Immediate Commercial Impact |
| January 3 |
FDA Issues Communication Communication about an Ongoing Safety
Review of ESAs |
| January 4 |
2007 - The Year in Drugs |
| January 4 |
Illumina Announces Corporate Reorganization |
| January 4 |
BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture |
| January 4 |
WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. |
| January 4 |
IMS Health Announces Restructuring Actions to Improve Operating
Efficiencies, Address Client Priorities |
| January 4 |
Berkery Noyes Represented The Thomson Corporation in the Sale of
CenterWatch and New England Institutional Review Board to Jobson
Medical Information |
| January 7 |
Magen BioSciences Licenses Dermatology Assets from Lilly |
| January 7 |
Contract Research Organization Market - What Pharmaceutical and
Biotechnology Companies Want |
| January 7 |
Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug
Candidate |
| January 7 |
VaxGen Provides Update on Raven Transaction Progress |
| January 7 |
Boston Scientific Completes Sale of Auditory Business and Drug Pump
Development Program |
| January 7 |
Access Pharmaceuticals Closes Acquisition of Somanta
Pharmaceuticals |
| January 7 |
Encorium Group, Inc. Announces the Signing of a $2.0 Million
Contract for Data Management Services for a Global Pharmaceutical
Company |
| January 7 |
ATMI Acquires LevTech |
| January 7 |
Faust Pharmaceuticals Announces Research Agreement with Takeda |
| January 7 |
Inclinix Secures $10 Million in Expansion Funding |
| January 7 |
Omnicom's BBDO Invests in China's Shunya Communications Group |
| January 7 |
NextGen Sciences Announces Commercial Alliance with Paragon
Bioservices, Inc |
| January 7 |
Boston Scientific Completes Sale of Cardiac Surgery and Vascular
Surgery Businesses |
| January 7 |
Tacere Therapeutics Enters Collaboration and License Agreement With
Pfizer To Develop and Commercialize RNAi Hepatitis C Drug |
| January 7 |
The GVK BIO Clinical Pharmacology Unit Granted Major Accreditations |
| January 7 |
Synovate Healthcare Boosts Global Oncology Portfolio Through
Acquisition of Oncology Inc. |
| January 7 |
FDA MedWatch - Bisphosphonates- Possible Cause of Severe and
Sometimes Incapacitating Bone, Joint, and/or Muscle Pain |
| January 7 |
MedImmune Broadens Focus of Venture Capital Fund to Include New
Therapeutic Areas |
| January 7 |
Cambrex Signs Agreement To Acquire ProSyntest AS |
| January 7 |
Court of Appeals Upholds Verdicts in Favor of Cordis Corporation on
Patents Infringed by Medtronic, Inc. and Boston Scientific
Corporation |
| January 8 |
Cetero Research Adds DGD Research, Enhancing Their Therapeutic
Capabilities and Expertise to Include Endocrinology and Metabolic
Disorders |
| January 8 |
Reckitt Benckiser Receives Hart-Scott-Rodino Antitrust Clearance
for Acquisition of Adams Respiratory Therapeutics |
| January 8 |
Cetero Research Adds DGD Research, Enhancing Their Therapeutic
Capabilities and Expertise to Include Endocrinology and Metabolic
Disorders |
| January 8 |
Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF
Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases |
| January 8 |
NicOx Signs Extension of Ophthalmology Agreement With Pfizer |
| January 8 |
Boston Scientific Announces Court Decision |
| January 8 |
Seattle Genetics Earns Milestone Payment from Initiation of SGN-40
Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin
Lymphoma |
| January 8 |
Genzyme and Isis Announce Strategic Alliance Including Exclusive
Worldwide License of Mipomersen |
| January 8 |
Introducing Latest Study on 'Optimizing Partnerships with Contract
Organizations: Effective Management, Key Issues and the Development
of Virtual Pharmacos' |
| January 8 |
Committee on Energy and Commerce Opens Investigation into Celebrity
Drug Endorsements |
| January 8 |
ViroPharma Provides Update on Vancocin |
| January 8 |
FDA Warnings Affected Prescriptions of Antidepressants to Youth |
| January 8 |
Removing Thimerosal from Vaccines Did Not Reduce Autism Cases in
California |
| January 8 |
PII Acquires Pharmaterials Ltd |
| January 8 |
Iris Pharma and Clirophtha Merger Creates Unique Ophthalmology CRO |
| January 8 |
Iris Pharma and Clirophtha Merger Creates Unique Ophthalmology CRO |
| January 8 |
Biogen Idec and PDL BioPharma License the Rights to Develop
Volociximab in Ophthalmic Indications to Ophthotech |
| January 8 |
ResearchPoint Global Announces Addition of M2S to Network |
| January 8 |
Acquisition of Lymphatix Brings VEGF Gene Rights and Technology to
Catalyse Ark's Gene-Based Medicine Programmes |
| January 8 |
Praxis' Patient Recruitment Campaign Saves 300 Days off Enrollment
for Women's Health Study |
| January 8 |
Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue |
| January 8 |
Amgen Updates 2007 Adjusted EPS Guidance and Outlines 2008 Expense
Outlook at the JP Morgan Healthcare Conference |
| January 8 |
First Consulting Group Prevails at Court Hearing |
| January 9 |
Avista Capital Partners Completes Acquisition of Bristol-Myers
Squibb Medical Imaging |
| January 9 |
D.C. Council Passes Safe Rx Act |
| January 9 |
Morphotek Announces Agreement for the Development of Antibodies to
Treat Prostate Cancer |
| January 9 |
Barr Confirms Patent Challenge of Eloxatin Injectable, 5mg/mL |
| January 9 |
PPRS Renegotiation: Joint ABPI/DH Statement |
| January 9 |
Quintiles Central Lab, Clinical Development in China to Expand,
Relocate to New Facility |
| January 10 |
Pfizer Wins Key New York State Court Ruling on Celebrex |
| January 10 |
Omeros Corporation Files Registration Statement for Proposed
Initial Public Offering |
| January 10 |
Invitrogen Announces Acquisition of CellzDirect |
| January 10 |
Encorium Group, Inc. Announces Signing of $1.7 Million in Contracts
with Leading International Biotechnology Company for Clinical
Trials in Oncology and Rheumatology |
| January 10 |
Jerini Announces Collaboration Agreement with Baxter to Develop
Novel Peptide for Use in Therapeutic Protein Purification |
| January 10 |
Noven Receives FDA Warning Letter Related to Mid-2007 Facility
Inspection |
| January 11 |
Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File
Lawsuits Against Several Companies for Patent Infringement |
| January 11 |
RxElite Announces Acquisition of Assets of FineTech Laboratories |
| January 11 |
CSS Informatics Signs Solutions Partner Agreement with Nimbus
Partners |
| January 11 |
Atlantis Holding Corp. Announces Merger With Medical Institutional
Services, Inc. |
| January 14 |
Compugen Announces GPCR Ligand Discovery and License Option
Agreement With Merck |
| January 14 |
Inspire Announces Its Termination of Bilastine Licensing Agreement |
| January 14 |
Pfizer Receives Initial Communication from U.S. Patent and
Trademark Office Regarding Lipitor Basic Patent |
| January 14 |
Thimerosal-Autism Link Rejected by Maryland Court |
| January 14 |
Galapagos Extends Drug Discovery Collaboration with Lilly in
Nuclear Hormone Receptor Research |
| January 14 |
BLM, the Leading Independent Agency, to Combine with Arena Media
Communications |
| January 14 |
A.P. Pharma Announces Executive Officer Departure |
| January 14 |
Bridge Laboratories Receives $18 Million Financial Backing |
| January 14 |
Supreme Court Declines to Consider Whether Those Near Death Have
Right of Access to Experimental Drugs |
| January 15 |
Genentech Announces Full Year and Fourth Quarter 2007 Results |
| January 15 |
Forest Laboratories, Inc. Reports Q3'08 Diluted Earnings Per Share
of $0.96. Raises FY2008 EPS Guidance Range to $3.35-$3.45 Excluding
$0.15 per Share Licensing Charge |
| January 15 |
Novo Nordisk Refocuses Its Activities Within Inhaled Insulin and
Discontinues the Development of AERx |
| January 15 |
Reps. Dingell, Stupak to Continue ENHANCE Trial Investigation |
| January 15 |
First Head to Head Study Comparing Crestor and Lipitor Effects on
the Treatment of Atherosclerosis |
| January 15 |
Akrimax Pharmaceuticals Purchases Rouses Point Plant |
| January 16 |
ACC Statement on Enhance Trial |
| January 16 |
EU Antitrust: Commission Launches Sector Inquiry Into
Pharmaceuticals with Unannounced Inspections |
| January 16 |
NitroMed Reports on BiDil XR Progress Following FDA Meeting,
Announces Restructuring and Suspension of BiDil Sales Force, and
Retains Investment Bank to Advise on Strategic Options |
| January 16 |
ImpactRx Broadens Innovative Research Capability Through
Acquisition of Paragon Research and Consulting |
| January 16 |
Sandoz Fully Cooperating with European Commission Investigation of
the Pharmaceuticals Industry |
| January 16 |
HIV/AIDS Update - Reyataz (atazanavir) Package Insert Revisions |
| January 16 |
Canon Communications to Launch New Event for Drug and Medical
Device Marketing |
| January 16 |
FDA Issues a Public Health Advisory on Edetate Disodium (Marketed
as Endrate and Generic Products) |
| January 17 |
QLT Announces Visudyne Sales for Fourth Quarter and Fiscal Year
2007 |
| January 17 |
QLT Inc. Announces Initial Steps in Strategic Restructuring |
| January 17 |
Ventana Responds to Extension of Roche's Unsolicited Tender Offer |
| January 17 |
Novartis Achieves Record Results in 2007 Underscoring Benefits of
Strategic Healthcare Portfolio |
| January 17 |
Reps. Dingell, Stupak Raise Concerns, Questions on ENHANCE Trial |
| January 17 |
AAJ Demands FDA Withdraw Rule Allowing Drug Companies to Claim
Immunity for Failing to Warn Patients of Potential Drug Hazards |
| January 17 |
FDA MedWatch - Edetate Disodium (marketed as Endrate and generic
products) - Important Safety Considerations For Healthcare
Professionals |
| January 17 |
Eisai and MGI Pharma Announce Early Termination of HSR Waiting
Period for Eisai's Acquisition of MGI Pharma |
| January 17 |
Genedata Provides Expressionist Platform to Eisai Research
Institute |
| January 17 |
Malvern Instruments Acquires Viscotek Corporation |
| January 18 |
Jan Marini Skin Research Suspends Sales of Popular Eyelash Products |
| January 18 |
StemCells, Inc. Provides Batten's Clinical Trial Update |
| January 18 |
Actavis Acquires Italian Manufacturing Site from Pfizer |
| January 18 |
Roche Invests 430 Million Swiss Francs at Sites in Germany and
Switzerland Centres for the Research, Development, Production and
Filling of Innovative Biopharmaceuticals to be Expanded |
| January 18 |
U.S. Appeals Court Upholds Finding that Abbott Infringed
Innogenetics’ HCV Genotyping Patent, and Orders Abbott to Pay
Innogenetics Monetary Damages and Sanctions |
| January 18 |
Pfizer Statement on Chantix (varenicline) Labeling Update in the
United States |
| January 18 |
GTC Biotherapeutics Receives Notice Related to Nasdaq Minimum
Closing Bid Price Rule |
| January 18 |
Schering-Plough CEO to Buy $2 Million in Common Shares |
| January 18 |
New Jersey Attorney General Announces Subpoena of Pharmaceutical
Firm Over Marketing of Injectable Drug Enbrel |
| January 22 |
CytRx Provides Update on Phase IIb Arimoclomol Clinical Trial for
ALS |
| January 22 |
Ortho Evra Prescribing Information Updated |
| January 22 |
Roche to Acquire Ventana for $89.50 per share |
| January 22 |
GSK Does Not Option XL784 for Further Development |
| January 22 |
Wyeth and Teva Pharmaceuticals Extend the Standstill Period
Relating to Teva's Launch of Generic Pantoprazole |
| January 22 |
19 Percent of Office-Based Physicians Refuse to See Pharmaceutical,
Biotech and Medical Device Sales Reps |
| January 22 |
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor
of the Hedgehog Pathway |
| January 22 |
Aureon Laboratories to Collaborate with Pfizer, Inc. to Establish
Quantitative Biometrics for Assessing Therapeutic Response of
Prostate Cancer Patients Treated with Hormone Therapy |
| January 22 |
Teva to Acquire CoGenesys |
| January 22 |
Elsevier Acquires Edra S.p.A |
| January 23 |
Abbott Reports 16.1 Percent Sales Growth in Fourth Quarter |
| January 23 |
Reps. Dingell, Stupak Continue Enhance Trial Inquiry |
| January 23 |
Oversight and Government Reform Committee Chairman Waxman Requests
FDA Provide Documents Regarding Drug Company Marketing Loophole |
| January 23 |
Paul Capital Healthcare Purchases Additional Royalty Interest in
GlaxoSmithKline's Rotarix |
| January 23 |
Eisai Announces Satisfaction of Conditions to Tender Offer for MGI
Pharma Shares |
| January 23 |
Pfizer Reports Fourth-Quarter and Full-Year 2007 Results and 2008
Financial Guidance |
| January 23 |
Bayer Establishes US Special Access Program for Leukine While
Replacing Current Liquid Formulation |
| January 23 |
Dalton Medicinal Chemistry Partners Achieves Another Milestone in
Collaboration with Boehringer Ingelheim (Canada) Ltd. |
| January 23 |
U.S. Federal Trade Commission Clears Global Licensing and
Development Agreement Between BioMS Medical and Lilly |
| January 23 |
Direvo to Collaborate with Medimmune on Therapeutic Protease for
the Treatment of CNS Diseases |
| January 23 |
U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT
Request: Government Finds Prior Art Submitted By PUBPAT Invalidates
All of Gilead Sciences' Claims |
| January 24 |
Baxter Achieves Record Sales and Earnings for Full-Year 2007 |
| January 24 |
GlaxoSmithKline and TB Alliance Renew Tuberculosis Drug Discovery
Program |
| January 24 |
Stanford Study Finds Transplant Patient Thrives 2 Years After
Stopping Immunosuppressive Drugs |
| January 25 |
Amgen's Fourth Quarter 2007 Adjusted Earnings Per Share (EPS)
Increased 11 Percent to $1.00; Full Year 2007 Adjusted EPS
Increased 10 Percent to $4.29 |
| January 25 |
TransTech Pharma, Inc. Acquires Three Programs for the Treatment of
Metabolic Disorders from Novo Nordisk |
| January 25 |
Allergan, Inc. Comments on Botox (Botulinum Toxin Type A) Safety
Profile |
| January 25 |
ApoCell to Conduct Studies in Support of Novel Pfizer Cancer Drug
Trial |
| January 25 |
LabCorp Announces Definitive Agreement to Acquire Tandem Labs, Inc. |
| January 25 |
EMEA Statement on the Safety of Gardasil |
| January 25 |
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical
Trial of Second Generation Niacin Receptor Agonist Under Its
Collaboration With Merck & Co., Inc. |
| January 25 |
EMEA Recommends New Warnings and Contraindications for
Rosiglitazone |
| January 25 |
Sen. Grassley Asks Questions About Controversy Over Delayed Release
of Drug Study Involving Vytorin |
| January 25 |
MicroIslet Announces Management Change and Receives Working Capital
Loan |
| January 25 |
FDA Issues Early Communication about an Ongoing Review of Vytorin |
| January 28 |
Over-the-counter eardrops may cause hearing loss or damage
|
| January 28 |
Allergan, Inc. Responds to Public Citizen's Allegation Regarding a
Fatality Following Botox Cosmetic Treatment |
| January 28 |
Merck Receives Not Approvable Letter from FDA for OTC Mevacor
(lovastatin) 20 mg |
| January 28 |
German Federal Cartel Office Clears Celgene to Acquire Pharmion |
| January 28 |
Abbott and Eisai Announce Changes in the Sales Scheme in Japan for
Adalimumab, A Fully Human Monoclonal Anti-TNF- Antibody |
| January 28 |
Gastrotech Signs Licensing Agreement with Eli Lilly Following
Positive Clinical Data on Compound for Irritable Bowel Syndrome |
| January 28 |
Canon Communications Announces Details of Drug Development Summit |
| January 28 |
Bausch & Lomb and CrystalGenomics Announce R&D
Collaboration |
| January 29 |
Lilly Caps Successful Year with Strong Fourth-Quarter Results |
| January 29 |
Eisai Completes Acquisition of MGI Pharma |
| January 29 |
Theratechnologies Announces Review of Strategic Alternatives and
Filing of Preliminary Base Shelf Prospectus for Up to $35 Million
Equity Financing |
| January 29 |
PAION Agreement with Lundbeck Comes Into Force, Securing Future
Desmoteplase Development and EUR 8 Million Upfront-payment to PAION |
| January 29 |
U.S. Pharmacopeia 8th Annual MEDMARX Report Indicates
Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors
Nationwide |
| January 30 |
FDA Sends Warning Letter to Novartis Vaccines and Diagnostics |
| January 30 |
Teva Announces Wyeth Voids Standstill Agreement on Generic Protonix |
| January 30 |
Merck Announces 2007 Financial Results Reflecting Revenue Growth
from Key Products |
| January 30 |
Wyeth Announces Launch of Own Generic Version of Protonix |
| January 30 |
Neose Announces Discontinuation of NE-180 Program |
| January 30 |
Kyowa Hakko Nine-month Operating Income up 20.6%; Raises Full-year
Forecasts |
| January 30 |
Record Operating Results for Roche Again in 2007 |
| January 30 |
Taisho Revises Earnings Forecasts for FY2007 Full Year |
| January 30 |
Prasco to Distribute Wyeth's Own Generic Versions of Protonix
Delayed-Release Tablets |
| January 30 |
Allergan Reports Fourth Quarter Operating Results |
| January 30 |
Common Drug-Releasing Coronary Stents Appear to Have Similar
Clinical Outcomes |
| January 30 |
Solvay Pharmaceuticals, Inc. Announces Retirement of CEO Laurence
Downey and Appointment of Stephen Hill as New President and Chief
Executive Officer |
| January 31 |
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full
Year |
| January 31 |
P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces
Plan to Create Stand-Alone Coffee Company |
| January 31 |
ImClone Systems Reports Fourth Quarter and Full Year 2007 Financial
Results |
| January 31 |
Bristol-Myers Squibb Company Reports Financial Results for the
Fourth Quarter and Twelve Months of 2007 |
| January 31 |
PsychoGenics Expands Drug Discovery Relationship with Eli Lilly and
Company |
| January 31 |
Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and
Expands Commercial Team to Support Zevalin Sales and Applications
Seeking Two Product Approvals in 2009 |
| January 31 |
AstraZeneca PLC, Fourth Quarter and Full Year Results 2007 |
| January 31 |
Novo Nordisk: Financial statement for 2007 |
| January 31 |
Innate Pharma and Novo Nordisk A/S Partnership Refocused on the
Inflammatory Field |
| January 31 |
FDA MedWatch- Antiepileptic Drugs- FDA Analysis Showed Patients
Receiving Antiepileptic Drugs Had Approximately Twice The Risk of
Suicidal Behavior Or Ideation |
